Previous close | 25.31 |
Open | 25.21 |
Bid | 25.75 x 200 |
Ask | 26.02 x 100 |
Day's range | 25.21 - 26.00 |
52-week range | 6.40 - 30.27 |
Volume | |
Avg. volume | 1,274,452 |
Market cap | 2.227B |
Beta (5Y monthly) | 0.95 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Key Clinical Trials Show Promise as Company Strengthens Financial Position
Joshua Brumm, CEO & President of Dyne Therapeutics Inc (NASDAQ:DYN), has sold 100,000 shares of the company on March 1, 2024, according to a recent SEC Filing.
In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months […]